AHA 2020 Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.
AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.
AHA 2020 Evolocumab additionally given to statins in ASCVD patients significantly reduced the risk of developing complex coronary disease that needs revascularization, including complex PCI or CABG.
AHA 2020 This subanalysis of THALES showed that ticagrelor in combination with aspirin significantly reduced the 30-day risk of stroke or death compared to aspirin in high-risk patients with ipsilateral atherosclerotic stenosis.
AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.
AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.
AHA 2020 In individuals with intermediate CV risk and without CVD history, a combination of polypill plus aspirin reduced the primary outcome of CVD events compared to double placebo.
AHA 2020 The discussant of the Short DAPT trial, Róisín Colleran, gives a brief summary of the results and discusses the strengths and limitations of the trial.
AHA 2020 The primary CV endpoint was reduced by the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared to placebo in patients with diabetes and CKD, and in patients with diabetes and ADHF.
AHA 2020 Although elective PCI is quite safe, myocardial injury can be observed within 48 hours of PCI. The ALPHEUS trial examined the effect of type of antiplatelet therapy on myocardial damage in these patients.
AHA 2020 The OMEMI trial found no beneficial effects on CV outcomes and all-cause death by omega-3 fatty acid supplementation in elderly patients after MI, compared to patients receiving placebo.
AHA 2020 The STRENGTH trial found that omega-3 carboxylic acid supplementation had no beneficiary MACE outcome in patients with established or high-risk of CVD compared to placebo.